Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Boston Scientific ( (BSX) ) has provided an update.
On July 21, 2026, Boston Scientific’s board approved a new global restructuring program, the 2026 Restructuring Plan, aimed at driving sustained cost efficiencies and supporting continued growth by realigning its structure and resources with strategic priorities. The plan focuses on supply chain optimization, including transferring production lines among facilities, and targeted functional and organizational changes to enhance long-term operational efficiency.
The restructuring, to be initiated in 2026 and substantially completed by the end of 2029, is expected to create new roles in growth areas while also leading to some headcount reductions. Boston Scientific estimates total pre-tax charges of $700 million to $800 million, with $600 million to $700 million in future cash outlays, and anticipates reducing gross annual pre-tax expenses by about $500 million, with a substantial portion of the savings earmarked for reinvestment in strategic growth initiatives.
The most recent analyst rating on (BSX) stock is a Buy
with a $85.00 price target.
To see the full list of analyst forecasts on Boston Scientific stock,
see the BSX Stock Forecast page.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Neutral.
The score is anchored by strong underlying financial performance (rising revenue scale, improving margins and returns) and a moderate P/E. It is offset by weak price trends and negative momentum (trading below all key moving averages) plus a more cautious earnings-call outlook with lowered guidance and margin/product headwinds.
To see Spark’s full report on BSX stock,
click here.
More about Boston Scientific
Boston Scientific Corporation is a global medical technology company that develops and manufactures devices used in a wide range of interventional medical specialties. Its portfolio spans cardiovascular, rhythm management, endoscopy and other minimally invasive therapies, with a focus on supporting hospitals and clinicians in major healthcare markets worldwide.
Average Trading Volume: 20,207,654
Technical Sentiment Signal: Strong Sell
Current Market Cap: $65.77B
Find detailed analytics on BSX stock on TipRanks’ Stock Analysis page.